0001104659-23-068345.txt : 20230606 0001104659-23-068345.hdr.sgml : 20230606 20230606080740 ACCESSION NUMBER: 0001104659-23-068345 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20230602 FILED AS OF DATE: 20230606 DATE AS OF CHANGE: 20230606 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Komjathy Andrew CENTRAL INDEX KEY: 0001788465 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37467 FILM NUMBER: 23994934 MAIL ADDRESS: STREET 1: CATABASIS PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, SUITE B14202 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Astria Therapeutics, Inc. CENTRAL INDEX KEY: 0001454789 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 STATE STREET STREET 2: SUITE 1400 CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 617-349-1971 MAIL ADDRESS: STREET 1: 75 STATE STREET STREET 2: SUITE 1400 CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: CATABASIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20090127 4 1 tm2317752-11_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-06-02 0 0001454789 Astria Therapeutics, Inc. ATXS 0001788465 Komjathy Andrew C/O ASTRIA THERAPEUTICS, INC. 75 STATE STREET, SUITE 1400 BOSTON, MA 02109 0 1 0 0 Chief Commercial Officer 0 Stock Option (Right to Buy) 13.36 2023-06-02 4 A 0 80000 0 A 2033-01-31 Common Stock 80000 80000 D This option was by granted effective as of February 1, 2023, subject to stockholder approval of an amendment to Astria Therapeutics, Inc.'s (the "Company") Amended and Restated 2015 Stock Incentive Plan to increase the number of shares available for issuance thereunder by 4,300,000 (the "Stock Plan Amendment Proposal"). The Company's stockholders approved the Stock Plan Amendment Proposal on June 2, 2023. This option was granted on February 1, 2023 and is subject to vesting over a four-year period, with 25% of the 80,000 shares underlying the option upon grant vesting on the first anniversary of February 1, 2023 and the remainder vesting over the ensuing three years in equal monthly installments. Exhibit 24 - Power of Attorney /s/ Ben Harshbarger, as attorney-in-fact for Andrew Komjathy 2023-06-06 EX-24 2 tm2317752d11_ex24.htm EXHIBIT 24

 

Exhibit 24

 

 

 

75 State Street, Suite 1400, Boston MA 02109

 

LIMITED POWER OF ATTORNEY

FOR SECTION 16 REPORTING OBLIGATIONS

 

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Jill C. Milne, Ben Harshbarger and Noah Clauser signing singly and each acting individually, as the undersigned's true and lawful attorney-in-fact with full power and authority as hereinafter described to:

 

(1)           execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Astria Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section l6(a) of the Securities Exchange Act of 1934 and the rules thereunder (the "Exchange Act");

 

(2)           do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the "SEC") and any stock exchange or similar authority, including without limitation the filing of a Form ID, Update Passphrase, or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

 

(3)           seek or obtain, as the undersigned's representative and on the undersigned's behalf, information regarding transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to such attorney-in-fact and approves and ratifies any such release of information; and

 

(4)           take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned's responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of June 2, 2023.

 

  Sign: /s/ Andrew A. Komjathy
  Name: Andrew A. Komjathy

 

 

 

GRAPHIC 3 tm2317752d11_ex24img001.jpg GRAPHIC begin 644 tm2317752d11_ex24img001.jpg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